What is Biofortuna?
Biofortuna operates as a prominent contract development and manufacturing organization (CDMO) specializing in critical areas such as assay development, cell line quality control, and comprehensive laboratory services. The company offers a diverse suite of solutions, including molecular and immunoassay development, lyophilisation, and advanced controlled storage capabilities. Biofortuna serves a clientele of life science innovators who require specialized support to accelerate their diagnostic projects. Leveraging state-of-the-art facilities and a steadfast commitment to quality, Biofortuna is dedicated to mitigating risks and enhancing the speed to market for its clients' groundbreaking innovations.
How much funding has Biofortuna raised?
Biofortuna has raised a total of $14.9M across 7 funding rounds:
Other Financing Round
$1.6M
Other Financing Round
$2M
Other Financing Round
$3.3M
Unspecified
$2M
Unspecified
$2.3M
Unspecified
$1.6M
Unspecified
$2.1M
Other Financing Round (2010): $1.6M with participation from Enterprise Ventures and Catapult Ventures
Other Financing Round (2012): $2M led by Catapult Ventures, Foresight Group, Merseyside Special Investment Fund, and Enterprise Ventures
Other Financing Round (2012): $3.3M supported by Foresight Group, Merseyside Special Investment Fund, and Catapult Ventures
Unspecified (2013): $2M featuring Foresight Group, Catapult Ventures, Enterprise Ventures, and Merseyside Special Investment Fund
Unspecified (2015): $2.3M backed by Merseyside Special Investment Fund, Foresight Group, Catapult Ventures, and Enterprise Ventures
Unspecified (2016): $1.6M with participation from Catapult Ventures and EV Tech
Unspecified (2017): $2.1M, investors not publicly disclosed
Key Investors in Biofortuna
Catapult Ventures
Catapult Ventures is an investment firm specializing in tailored solutions for entrepreneurs and business owners, focusing on unlocking potential and supporting client goals. They are known for their strategic partnerships aimed at fostering growth and value.
Enterprise Ventures
Enterprise Ventures, part of EV Group, operates in the investment banking sector, providing capital and support to businesses. They are based in Manchester, UK, and focus on driving growth through strategic financial backing.
Merseyside Special Investment Fund
Merseyside Special Investment Fund (MSIF) is dedicated to empowering SMEs in the Liverpool City Region and North West England, offering business planning, funding advice, and access to angel networks to foster innovation and growth.
What's next for Biofortuna?
The substantial enterprise-level funding and recent strategic investment indicate Biofortuna is in a robust growth phase, likely focused on scaling operations, expanding its service offerings, and potentially pursuing strategic acquisitions or partnerships. This capital infusion will enable the company to further solidify its position as a key CDMO in the life sciences industry, supporting the development and manufacturing of advanced diagnostics and therapeutics. Continued investment in technology and talent will be crucial for Biofortuna to maintain its competitive edge and meet the evolving demands of its client base.
See full Biofortuna company page
